Skip to main content
. 2019 Mar 16;11(3):375. doi: 10.3390/cancers11030375

Figure 6.

Figure 6

The effect of pertuzumab on the proliferation of cells overexpressing EGFR, HER2 and HER3. (A) CHO-K1, (B) CHO-K6, (C) CHO-K13, (D) CHO-EGFR and (E) CHO-HER3 cell lines were treated with 0.1, 1 and 10 μg/mL pertuzumab, 10 μg/mL trastuzumab and their combination for 72 h, and then the living cell mass was evaluated by MTT assay. Five µM paclitaxel, 10 μg/mL human IgG and 20 μM CP-724714 were used as respectively antiproliferative, mock and HER2 inhibitor controls. * p < 0.05, ** p < 0.01, **** p < 0.0001.